Overview |
bs-8304R |
MTGR1 Polyclonal Antibody |
WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse, Rat, Dog, Cow, Pig, Horse, Chicken |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human MTGR1 |
321-420/604 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
9139 |
Nucleus |
AML1 MTG8; CBFA2T2; Core binding factor runt domain alpha subunit 2 translocated to 2; EHT; ETO homolog on chromosome 20; ETO homologous on chromosome 20; MTG 8 like protein; MTG 8 related protein 1; MTG8 like protein; MTG8 related protein 1; MTG8-like protein; MTG8-related protein 1; MTG8R_HUMAN; MTGR 1; Myeloid translocation gene related protein 1; Myeloid translocation related protein 1; Myeloid translocation-related protein 1; p85; Protein CBFA2T2; ZMYND 3; ZMYND3. |
May function as a complex with the chimeric protein RUNX1/AML1-CBFA2T1/MTG8 which is produced in acute myeloid leukemia with the chromosomal translocation t(8;21). May thus be involved in the repression of AML1-dependent transcription and the induction of G-CSF/CSF3-dependent cell growth. May be a tumor suppressor gene candidate involved in myeloid tumors with the deletion of the 20q11 region.Tissue specificity:Ubiquitously expressed in fetal and adult tissues. Highly expressed in adult brain, heart, lung, kidney, lymph node, appendix, thymus, testis, uterus, small intestine, prostate and thymus. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |